The combination of CD22-targeted Moxe and 2-DG showed synergy against 15 out of 17 B cell malignancy cell lines including BL, MCL, follicular lymphoma (FL), diffuse large B cell lymphoma (DLBCL), B cell acute lymphoblastic leukemia (ALL), and five patient-derived ALL and chronic lymphocytic leukemia (CLL) cells (Fig. 5A). This evidence concerns the gene CD22 and B-cell chronic lymphocytic leukemia.